Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View moreAbdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
PSMA-PET/CT effective in patients with kidney cancer
Study: PSMA PET/CT Agent May Rule Out csPCa in 93 Percent of PI-RADS 3 Lesions
Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
Investigating Absorbed Dose Response in 177Lu-DOTATATE for GEP-NETs
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients